Analytical Tools for In-depth Characterization of Cell and Gene Therapies
Advancements in immunology and genetic engineering have led to the development of cell and gene therapeutics for treating cancer, autoimmune and infectious diseases. Despite these promising results, developers of these complex “living” therapies continue to face challenges related to scalability and high manufacturing costs. Agilent offers a broad portfolio of cell analysis and genomics solutions to enable comprehensive product characterization to support next generation workflows.
Learning objectives
- Key challenges faced by developers of cell and gene therapies, from research to process development and manufacturing QC
- Workflows to characterize target product profile and gain deeper understanding of cell phenotype, function and mechanism of action
- Identify relevant Critical Quality Attributes (CQAs) at every stage to ensure therapeutic products meet safety and potency standards
Presenter: Aimee Chiavario (Director, Biopharma Marketing, Cell and Gene Therapies, Agilent Technologies, Inc.)
Aimee Chiavario is passionate about delivering “purpose-built” analytical tools to help scientists achieve their therapeutic research and development goals. She currently leads strategic biopharma marketing for Cell and Gene Therapies at Agilent Technologies. Prior to joining Agilent, she has held product marketing and R&D positions at ACEA Biosciences (now Agilent Technologies), Synthetic Genomics (now Codex DNA and Viridos) and Amgen, working on high throughput screening, assay development, and synthetic biology projects. She earned her MBA from Rady School of Management at University of California, San Diego and her undergraduate degree in Microbiology & Immunology from the University of British Columbia, Canada.
